Replies to post #83 on Catalyst Pharmaceutical Partners (CPRX)

[DonShimoda]

I've been in and out of CPRX a few times in the past but never felt that they were far enough along to warrant a core position. I really like the progress they have been making and, with 2 drugs in their pipeline, a $35mm market cap seems undervalued. fyi, Cowen recently started coverage with a "Outperform", so it looks like others are may be starting to take an interest as well.

[DonShimoda]

Dough,

Here's a link to the P2b trial:
http://clinicaltrials.gov/ct2/show/NCT01281202

btw, the company has partnered with the National Institute on Drug Abuse (NIDA)and the Department of Veterans Affairs who are picking up 75% of the trials' costs.